Predictability, efficacy and safety of radiosensitization of glioblastoma-initiating cells by the ATM inhibitor KU-60019

International Journal of Cancer

Volumn 135, Issue 2, 2014, Pages 479-491

  Vecchio, Donatella ^a   Daga, Antonio ^a   Carra, Elisa ^a   Marubbi, Daniela ^a,b   Baio, Gabriella ^a   Neumaier, Carlo E ^a   Vagge, Stefano ^a   Corvò, Renzo ^a   Pia Brisigotti, Maria ^a   Louis Ravetti, Jean ^a   Zunino, Annalisa ^a   Poggi, Alessandro ^a   Mascelli, Samantha ^c   Raso, Alessandro ^c   Frosina, Guido ^a  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

^c G GASLINI INSTITUTE   (Italy)

Author keywords

DNA damage response; glioblastoma; PI3K; radiotherapy; resistance; TP53

Indexed keywords

ANTINEOPLASTIC AGENT; KU 60019; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN P53; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL LINE; CANCER GRADING; CANCER RADIOTHERAPY; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFICACY; DRUG SAFETY; GLIOBLASTOMA; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INHIBITION KINETICS; IONIZING RADIATION; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; POINT MUTATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIOSENSITIZATION; TP53 GENE; TREATMENT RESPONSE; UPREGULATION;

DNA DAMAGE RESPONSE; GLIOBLASTOMA; PI3K; RADIOTHERAPY; RESISTANCE; TP53;

ANIMALS; BRAIN NEOPLASMS; CELL LINE, TUMOR; GLIOBLASTOMA; HUMANS; MICE; MORPHOLINES; NEOPLASTIC STEM CELLS; RADIATION TOLERANCE; RADIATION-SENSITIZING AGENTS; THIOXANTHENES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84900000610     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28680     Document Type: Article

References (19)

1. Van Meir EG, Hadjipanayis CG, Norden AD, et al. Exciting new advances in neuro-oncology: the avenue to a cure for malignant glioma. CA Cancer J Clin 2010; 60: 166-93.
2. Snuderl M, Fazlollahi L, Le LP, et al. Mosaic amplification of multiple receptor tyrosine kinase genes in glioblastoma. Cancer Cell 2011; 20: 810-17.
3. Ene CI, Fine HA,. Many tumors in one: a daunting therapeutic prospect. Cancer Cell 2011; 20: 695-7.
4. Frosina G,. DNA repair and resistance of gliomas to chemotherapy and radiotherapy. Mol Cancer Res 2009; 7: 989-99.
5. Ropolo M, Daga A, Griffero F, et al. Comparative analysis of DNA repair in stem and nonstem glioma cell cultures. Mol Cancer Res 2009; 7: 383-92.
6. Bao S, Wu Q, McLendon RE, et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 2006; 444: 756-60.
7. Raso A, Vecchio D, Cappelli E, et al. Characterization of glioma stem cells through multiple stem cell markers and their specific sensitization to double-strand break-inducing agents by pharmacological inhibition of ataxia telangiectasia mutated protein. Brain Pathol 2012; 22: 677-88.
8. Stracker TH, Roig I, Knobel PA, et al. The ATM signaling network in development and disease. Front Genet 2013; 4: 37.
9. Shiloh Y, Ziv Y,. The ATM protein kinase: regulating the cellular response to genotoxic stress, and more. Nat Rev Mol Cell Biol 2013; 14: 197-210.
10. Raso A, Mascelli S, Nozza P, et al. Troubleshooting fine-tuning procedures for qPCR system design. J Clin Lab Anal 2011; 25: 389-94.
11. Glaab WE, Tindall KR,. Mutation rate at the hprt locus in human cancer cell lines with specific mismatch repair-gene defects. Carcinogenesis 1997; 18: 1-8.
12. Ropolo M, Geroldi A, Degan P, et al. Accelerated repair and reduced mutagenicity of oxidative DNA damage in human bladder cells expressing the E. coli FPG protein. Int J Cancer 2006; 118: 1628-34.
13. Baker SG,. The central role of receiver operating characteristic (ROC) curves in evaluating tests for the early detection of cancer. J Natl Cancer Inst 2003; 95: 511-15.
14. Barak Y, Juven T, Haffner R, et al. Mdm2 expression is induced by wild type P53 activity. EMBO J 1993; 12: 461-8.
15. Vogelstein B, Lane D, Levine AJ,. Surfing the p53 network. Nature 2000; 408: 307-10.
16. Chalut KJ, Ekpenyong AE, Clegg WL, et al. Quantifying cellular differentiation by physical phenotype using digital holographic microscopy. Integr Biol (Camb) 2012; 4: 280-4.
17. Golding SE, Rosenberg E, Valerie N, et al. Improved ATM kinase inhibitor KU-60019 radiosensitizes glioma cells, compromises insulin, AKT and ERK prosurvival signaling, and inhibits migration and invasion. Mol Cancer Ther 2009; 8: 2894-902.
18. Biddlestone-Thorpe L, Sajjad M, Rosenberg E, et al. ATM kinase inhibition preferentially sensitizes p53-mutant glioma to ionizing radiation. Clin Cancer Res 2013; 19: 3189-200.
19. Stupp R, Hegi M, Weller M,. Neuro-oncology, a decade of temozolomide and beyond. Expert Rev Anticancer Ther 2010; 10: 1675-7.